Incannex Healthcare Ltd ADR

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company based in Sydney, Australia, focused on research and development of psychedelic medicines and therapies for patients with chronic diseases. Its pipeline includes IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide in Phase 2/3 clinical trials for obstructive sleep apnea, and PSX-001, an oral synthetic psilocybin treatment in Phase 2b development for generalized anxiety disorder. The company is also developing IHL-675A, an oral fixed-dose combination of synthetic cannabidiol and hydroxychloroquine sulphate, for rheumatoid arthritis and other inflammatory conditions including lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease.